Lucid Diagnostics Inc. (NASDAQ:LUCD) Given Average Rating of “Moderate Buy” by Analysts

Lucid Diagnostics Inc. (NASDAQ:LUCD) has been given an average rating of “Moderate Buy” by the five ratings firms that are currently covering the firm, MarketBeat.com reports. One investment analyst has rated the stock with a sell recommendation and four have assigned a buy recommendation to the company. The average 12-month price target among brokers that have issued a report on the stock in the last year is $3.9375.

Several analysts have issued reports on the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Lucid Diagnostics in a research report on Monday, December 29th. Needham & Company LLC reaffirmed a “buy” rating and set a $3.00 price objective on shares of Lucid Diagnostics in a research report on Thursday, November 13th. Wall Street Zen downgraded shares of Lucid Diagnostics from a “hold” rating to a “sell” rating in a report on Saturday, November 15th. Finally, Ascendiant Capital Markets increased their price target on shares of Lucid Diagnostics from $8.00 to $8.25 and gave the company a “buy” rating in a research report on Wednesday, December 10th.

Lucid Diagnostics Stock Performance

NASDAQ LUCD opened at $1.19 on Monday. Lucid Diagnostics has a one year low of $0.89 and a one year high of $1.80. The company has a market capitalization of $163.84 million, a price-to-earnings ratio of -1.14 and a beta of 1.22. The company’s 50-day simple moving average is $1.13 and its two-hundred day simple moving average is $1.12.

Lucid Diagnostics (NASDAQ:LUCD) last released its quarterly earnings data on Wednesday, November 12th. The company reported ($0.10) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.06) by ($0.04). The firm had revenue of $1.21 million for the quarter, compared to analysts’ expectations of $1.35 million. Equities analysts expect that Lucid Diagnostics will post -0.84 earnings per share for the current fiscal year.

Institutional Trading of Lucid Diagnostics

Several hedge funds and other institutional investors have recently made changes to their positions in LUCD. Two Seas Capital LP purchased a new position in Lucid Diagnostics during the 3rd quarter worth $3,030,000. Ghisallo Capital Management LLC acquired a new position in shares of Lucid Diagnostics during the third quarter valued at about $2,990,000. Aberdeen Group plc purchased a new position in shares of Lucid Diagnostics in the 3rd quarter valued at approximately $2,525,000. Geode Capital Management LLC boosted its stake in Lucid Diagnostics by 420.3% in the 2nd quarter. Geode Capital Management LLC now owns 1,577,369 shares of the company’s stock worth $1,814,000 after purchasing an additional 1,274,194 shares in the last quarter. Finally, Masters Capital Management LLC grew its position in Lucid Diagnostics by 46.6% during the 3rd quarter. Masters Capital Management LLC now owns 3,999,273 shares of the company’s stock worth $4,039,000 after purchasing an additional 1,272,000 shares during the last quarter. Hedge funds and other institutional investors own 74.01% of the company’s stock.

About Lucid Diagnostics

Lucid Diagnostics is a molecular diagnostics company focused on improving early detection of oral and oropharyngeal cancers. The company’s flagship offering, the LucidDx Oral Cytology Brush Test, combines a minimally invasive brush biopsy tool with proprietary laboratory analysis to identify cellular abnormalities indicative of malignancy. Samples collected in dental and medical offices are sent to Lucid’s CLIA-certified and CAP-accredited laboratory, where advanced imaging and cytopathology workflows generate diagnostic reports for clinicians and patients.

Since commencing commercial operations, Lucid Diagnostics has worked to integrate its testing platform into dental practices, oral surgery clinics and ENT specialists across the United States.